Ignite Creation Date:
2025-12-26 @ 2:41 PM
Ignite Modification Date:
2025-12-26 @ 2:41 PM
Study NCT ID:
NCT06832306
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2025-02-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
STimulation to Activate RespIration
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008224', 'term': 'Lymphoma, Follicular'}], 'ancestors': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': '2:1 Randomization treatment to control'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 30}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-05-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-10-20', 'studyFirstSubmitDate': '2025-02-06', 'studyFirstSubmitQcDate': '2025-02-14', 'lastUpdatePostDateStruct': {'date': '2025-10-22', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-02-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Successful device insertion, mapping, and initiation of stimulation within 18 hours of meeting readiness-to-stimulate criteria', 'timeFrame': 'Within 18 hours of meeting readiness to stimulate criteria'}, {'measure': 'Stimulation delivered on >50% of ventilator-triggered breaths (ascertained from continuous recordings stored in the Console)', 'timeFrame': '30 days'}, {'measure': 'Rehabilitation sessions delivered at least once per day on >50% of days when the patient was breathing in assisted (patient-triggered) mechanical ventilation for at least 12 hours', 'timeFrame': '30 days'}], 'secondaryOutcomes': [{'measure': 'Unanticipated serious adverse device events (USADE) and incidence of device- or procedure-related SAEs in the Treatment group', 'timeFrame': '30 days'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['ARDS (Moderate or Severe)', 'AHRF', 'Mechanically Ventilated ICU Patients']}, 'descriptionModule': {'briefSummary': 'Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Male or female, 18 years or older, and\n2. Able to provide informed consent or have a legally authorized representative (LAR) / Substitute Decision Maker (SDM) who can provide consent, and\n3. Have acute onset of new respiratory symptoms or dysfunction within the 2 weeks before onset of need for respiratory support, and\n4. Have moderate-to-severe arterial hypoxemia defined by one of:\n\n * PaO2:FiO2 ratio \\<≤200 mm Hg on PEEP ≥ 5 cm H2O, or\n * In the absence of an available arterial blood gas, SpO2 ≤97% on FiO2 ≥0.5 and PEEP ≥5 cm H2O with reliable SpO2 trace for the 2 hours immediately preceding eligibility assessment (this correlates to an upper limit of SpO2:FiO2 ratio of 235%) or\n * Are receiving inhaled nitric oxide for acute hypoxemia, or\n * Are being ventilated in the prone position for acute hypoxemia, and\n5. Have been mechanically ventilated for AHRF in the ICU for \\<72 hours at the time of enrolment, and\n6. Are expected to require invasive mechanical ventilation ≥ 48 hours after enrollment in the opinion of the treating clinician\n\nExclusion Criteria:\n\n1. Hypoxemia is primarily attributable to acute exacerbation of chronic obstructive pulmonary disease, status asthmaticus, cardiogenic pulmonary edema, or pulmonary embolism.\n2. Underlying chronic parenchymal lung disease that may make recovery/extubation a challenge (e.g., COPD, pulmonary fibrosis).\n3. Broncho-pleural fistula at the time of eligibility assessment.\n4. Severe hemodynamic instability (requiring norepinephrine or epinephrine \\> 0.5 mcg/kg/min)\n5. Require extracorporeal membrane oxygenation.\n6. Pre-existing neurological, neuromuscular or muscular disorder or known phrenic nerve injury that could affect the respiratory muscles.\n7. BMI \\>70 kg/m2.\n8. Contraindications to left internal jugular vein or left subclavian vein catheterization (e.g., infection at the access site, known central venous stenosis, septic thrombophlebitis, left internal jugular ECMO cannula in situ, poor target vessels).\n9. Patient expected to transition to fully palliative care within 72 hours of enrollment.\n10. Chronic severe liver disease (Child-Pugh Score ≥10)\n11. Treating clinician deems enrollment not clinically appropriate.\n12. Currently enrolled in any other study of an investigational drug or device, which may affect the outcomes of the current study.\n13. Any electrical device (implanted or external) that may be prone to interaction with or interference from the AeroNova System, including neurological pacing/stimulator devices and cardiac pacemakers and defibrillators.\n14. Known or suspected to be pregnant or lactating.'}, 'identificationModule': {'nctId': 'NCT06832306', 'acronym': 'STARI', 'briefTitle': 'STimulation to Activate RespIration', 'organization': {'class': 'INDUSTRY', 'fullName': 'Lungpacer Medical Inc.'}, 'officialTitle': 'A Clinical Study Evaluating Temporary Transvenous Diaphragm Neurostimulation in Mechanically Ventilated Patients With Acute Hypoxemic Respiratory Failure', 'orgStudyIdInfo': {'id': 'P-600'}, 'secondaryIdInfos': [{'id': '75A0123C00021', 'type': 'OTHER_GRANT', 'domain': 'Biomedical Advanced Research and Development Authority (BARDA)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment', 'description': 'Treatment group subjects will have the Catheter placed percutaneously into the left jugular vein or left subclavian vein. Mapping will identify the electrodes that stimulate the phrenic nerves and enable diaphragm contraction using the AeroNova Console. The stimulation level will be titrated to target a level of diaphragm activation equivalent to resting quiet breathing by adjusting the stimulation frequency and amplitude. Subjects will receive continuous stimulation plus standard of care lung-protective ventilation.', 'interventionNames': ['Device: Phrenic Nerve Stimulation']}, {'type': 'NO_INTERVENTION', 'label': 'Control', 'description': 'Standard of Care - Lung-protective ventilation'}], 'interventions': [{'name': 'Phrenic Nerve Stimulation', 'type': 'DEVICE', 'otherNames': ['Diaphragm neurostimulation-assisted ventilation (DNAV)'], 'description': 'During controlled MV when patients are not breathing, continuous diaphragm neurostimulation-assisted ventilation (DNAV) will be delivered in synchrony with each ventilator-delivered breath.', 'armGroupLabels': ['Treatment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92037', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California San Diego', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '71103', 'city': 'Shreveport', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Louisiana State University Health Sciences', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '19122', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Temple University', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '29203', 'city': 'Columbia', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Prisma Health', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': 'M5G 2C4', 'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'University Health Network (UHN)', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'centralContacts': [{'name': "Megan O'Toole", 'role': 'CONTACT', 'email': 'motoole@lungpacer.com', 'phone': '(484) 350-4530'}, {'name': 'STARI Study', 'role': 'CONTACT', 'email': 'STARIstudy@lungpacer.com', 'phone': '(484) 350-4530'}], 'overallOfficials': [{'name': 'Ewan Gohligher, MD, PhD, FRCPC', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Toronto General Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Lungpacer Medical Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}